**
In a striking contradiction to previous assurances from the Trump administration, a recent analysis led by Vermont Senator Bernie Sanders indicates that prescription drug prices in the United States have surged rather than declined since the implementation of the TrumpRx initiative. The report highlights alarming statistics, revealing that nearly all drug manufacturers involved in this programme have increased prices across hundreds of medications, leaving many Americans to grapple with the financial burden of their prescriptions.
Rising Prices Amid Promised Reductions
The 11-page analysis, shared with The Update Desk, underscores a troubling trend: 15 out of the 16 pharmaceutical companies participating in the TrumpRx project have raised their prices since the agreements were established late last year. The report draws on data from NAVLIN, a price tracking software, and reveals that a total of 337 drugs have seen price increases since January 21, 2025. Notably, treatments for severe conditions such as cancer and multiple sclerosis have seen some prices escalate by over £14,000 annually during the negotiations with the administration.
Senator Sanders, who serves as the ranking member on the Senate Health, Education, Labor and Pensions Committee, expressed his agreement with President Trump that the exorbitant cost of prescription drugs in the U.S. is unacceptable. However, he lamented the failure of the administration to deliver on its promise, stating, “Unfortunately, despite President Trump’s rhetoric, prescription drug prices in America have only gone up, not down, since he was elected.”
Critique of the TrumpRx Platform
The report also casts doubt on the effectiveness of the TrumpRx online platform designed to provide discounted prescription prices. It suggests that the platform does not yield substantial savings for patients and instead directs them towards higher-cost medications, potentially benefiting the pharmaceutical companies involved rather than consumers in need. The analysis argues that the platform misses an opportunity to promote lower-cost generic alternatives, which are not available through TrumpRx.
A spokesperson for the White House, Kush Desai, dismissed the report’s findings, arguing that it focuses on list prices, which do not accurately reflect the prices consumers pay at the pharmacy counter. He referenced Bureau of Labor Statistics data, claiming that actual prescription costs have declined since President Trump took office, marking the most significant three-month drop recorded since the 1960s.
Legislation to Address Drug Pricing
As the situation unfolds, Sanders and other senators have proposed new legislation aimed at compelling drug manufacturers to adjust their prices to align with those in peer countries such as Canada, Germany, and the United Kingdom. This proposed law would require that if companies fail to lower their prices, the government would facilitate the approval of affordable generic alternatives.
Senator Sanders urged the administration to take a more proactive stance against the pharmaceutical industry’s pricing practices, stating, “If the president is serious about taking on the greed of the pharmaceutical industry, he should support legislation I introduced to cut drug prices by more than half and ensure Americans pay no more than the Europeans or Canadians, saving over $180 billion a year.”
The Impact on American Consumers
The ramifications of these rising drug prices are profound. Recent polling by the health policy research non-profit KFF indicates that nearly one-third of American adults have opted for over-the-counter medications instead of their prescribed treatments due to cost concerns. Furthermore, one in five respondents admitted to cutting pills in half or skipping doses altogether to manage their expenses.
The report arrives in the lead-up to a Senate HELP committee hearing dedicated to the pressing issue of drug pricing, reflecting growing discontent among lawmakers and the public alike over the pharmaceutical industry’s practices.
Why it Matters
The findings from Senator Sanders’ report highlight a critical issue in American healthcare, where millions of individuals face the daunting choice between their health and financial stability. The persistent rise in drug prices, despite promises of reform, underscores the urgent need for comprehensive legislative action to ensure that life-saving medications remain accessible to all. As discussions surrounding drug pricing intensify, it is essential that policymakers prioritise the wellbeing of consumers over corporate profits to foster a healthcare system that truly serves the needs of the public.
